Eutilex faces rehabilitation and delisting risk

Rehabilitation started: On March 30, 2026, Seoul Bankruptcy Court decided to commence rehabilitation (Case 2026hohap1034).
Delisting risk: 2025 fiscal year audit opinion was disclaimer, triggering delisting; improvement period granted until April 10, 2027.
Financial deterioration: Consolidated sales of KRW 1.25 billion (previous quarter KRW 1.03 billion), operating loss of KRW 2.59 billion, net loss of KRW 2.65 billion, deficit of KRW 220.8 billion.
Liquidity crisis: Cash and cash equivalents of KRW 566 million (from KRW 4.4 billion at year-end), short-term borrowings of KRW 14.7 billion, debt ratio 155%.
Biotech pipeline: Clinical trials for EU307 etc. ongoing but no commercialized product; IT business accounts for most sales.
Management dispute and lawsuits: Multiple lawsuits including management rights, stock trading suspended since Feb 9, 2026.
No shareholder return: No share buyback/cancellation or dividend plan.

ADVERTISEMENT (250px+)